Teva Pharmaceutical Industries
TEVA
39.23
+0.69
+1.79%
Teva Pharmaceutical Industries
US · TEVA
#471 by market cap
Listed 1970
39.23
+0.69
+1.79%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:01
Recent news
-
Rating change
Teva Pharmaceuticals Price Target Announced at $52.00/Share by HC Wainwright & Co.Dow Jones · 2026/11/2
-
Company notice
TEVA PHARMACEUTICAL INDUSTRIES | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Phoenix Holdings Ltd.(4.83%)SEC · 2024/4/9
-
Company notice
Teva Pharmaceutical Industries | 3: Initial statement of beneficial ownership of securities-Officer McAvoy David R.SEC · 2024/3/6
-
Barclays Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $50Market Newswire · 2026/11/19
-
Company notice
Teva Pharmaceutical Industries | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Phoenix Holdings Ltd.(4.83%)SEC · 2024/4/9
-
HC Wainwright & Co. Reiterates Buy on Teva Pharmaceutical Indus, Maintains $54 Price TargetBenzinga · 2026/11/17
-
Rating change
A Quick Look at Today's Ratings for Teva Pharmaceutical Industries(TEVA.US), With a Forecast Between $54 to $57Market Newswire · 2026/11/13
-
Rating change
Barclays Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $47Market Newswire · 2026/10/16
-
H.C. Wainwright Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $54Market Newswire · 2026/11/18
-
Company notice
Teva Pharmaceutical Industries | SC 13G: Statement of acquisition of beneficial ownership by individuals-The Phoenix Holdings Ltd.(5.40%)SEC · 2024/2/1
-
TD Cowen Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $57Market Newswire · 2026/11/13
-
Company notice
Teva Pharmaceutical Industries | 4: Statement of changes in beneficial ownership of securities-Officer McAvoy David R.SEC · 2024/3/6
-
Rating change
H.C. Wainwright Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $54Market Newswire · 2026/11/4
-
Rating change
A Quick Look at Today's Ratings for Teva Pharmaceutical Industries(TEVA.US), With a Forecast Between $47 to $55Market Newswire · 2026/11/5
-
Rating change
Teva Pharmaceuticals Price Target Maintained With a $54.00/Share by HC Wainwright & Co.Dow Jones · 2026/11/17
-
Rating change
HC Wainwright & Co. Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $54Benzinga · 2026/11/4
-
Rating change
Teva Pharmaceuticals Initiated at Buy by HC Wainwright & Co.Dow Jones · 2026/11/2
-
Rating change
HC Wainwright & Co. Initiates Coverage On Teva Pharmaceutical Indus With Buy Rating, Announces Price Target of $52Benzinga · 2026/11/2
-
Rating change
Scotiabank Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $47Market Newswire · 2026/11/4
-
Leerink Partners Initiates Teva Pharmaceutical Industries(TEVA.US) With Buy RatingMarket Newswire · 2026/11/20
-
Rating change
Barclays Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $42Market Newswire · 2026/10/13
-
Rating change
TD Cowen Initiates Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Announces Target Price $55Market Newswire · 2026/10/2
-
Rating change
Leader Capital Markets Initiates Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Announces Target Price $49.95Market Newswire · 2026/10/13
-
Rating change
BofA Securities Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $43Market Newswire · 2026/10/9
-
Teva Q3 Adj. Gross Margin 58.7%, Up 345 Bps YoYBenzinga · 2026/11/3
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:01:26 · For reference only, not investment advice and not tailored to your situation.
Teva Pharmaceutical Industries discussion 0 comments